An immunohistochemical analysis of PD-L1 protein expression in surgically resected small cell lung cancer using different antibodies and criteria

Anticancer Research

Volumn 36, Issue 7, 2016, Pages 3409-3412

  Takada, Kazuki ^a   Toyokawa, Gouji ^a   Okamoto, Tatsuro ^a   Akamine, Takaki ^a   Takamori, Shinkichi ^a   Katsura, Masakazu ^a   Fujishita, Takatoshi ^a   Shoji, Fumihiro ^a   Oda, Yoshinao ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; PD L1; Small cell lung cancer

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 28-8; MONOCLONAL ANTIBODY E1L3N; MONOCLONAL ANTIBODY SP142; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; ANTIBODY; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ALLRED SCORE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SMALL CELL LUNG CANCER; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; SMALL CELL LUNG CARCINOMA;

ANTIBODIES; ANTIGENS, CD274; BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 84992026445     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J 62: 10-29, 2012.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A and Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F and Brahmer JR: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.
5. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity of PDL1 expression in non-small-cell lung cancer. JAMA Oncol 2: 46-54, 2016.
6. Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, Zander T, Wolf J and Buettner R: PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51: 421-426, 2015.
7. Ott PA, Fernandez MEE, Hiret S, Kim DW, Moss RA, Winser T, Yuan S, Cheng JD, Piperdi B and Mehnert JM: Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 33, 2015 (suppl; abstr 7502).
8. Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M and Hoshino T: Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 10: 426-430, 2015.
9. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
10. Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, Ott PA, Pietanza MC, Horn L, Le DT, Morse M, Lopez-Martin JA, Ascierto PA, Christensen O, Grosso J, Simon JS, Lin CS and Eder JP: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol 33, 2015 (suppl; abstr 7503).
11. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS and Hodi FS: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567, 2014.